Payment overview · 2025
General Payments
$379.51
21 reported records · 14 companies
Healthcare provider profile · identity verified
Matthew John Dvorchak, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HASTINGS, PA · NPI 1902846405
Verified facts
What the public records show
CMS Open Payments records show Matthew John Dvorchak, M.D. received $379.51 in general payments during 2025 across 21 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $69.92 | 18.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $59.62 | 15.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.10 | 9.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $33.11 | 8.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.77 | 5.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.67 | 5.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.47 | 5.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.39 | 5.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.81 | 5.0% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.56 | 4.4% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.01 | 4.2% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.92 | 4.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.80 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.36 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $379.51 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $69.92 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.72 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $33.11 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $20.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 141 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 81 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
30 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
81 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
141 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 529 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 491 | 114 |
| Atorvastatin Calcium | Atorvastatin Calcium | 391 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 365 | 74 |
| Losartan Potassium | Losartan Potassium | 332 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 326 | 88 |
| Furosemide | Furosemide | 279 | 72 |
| Lorazepam | Lorazepam | 226 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 59 |
| Gabapentin | Gabapentin | 210 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 56 |
| Celecoxib | Celecoxib | 205 | 54 |
| Potassium Chloride | Potassium Chloride | 204 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 189 | 38 |
| Sertraline Hcl | Sertraline Hcl | 180 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 174 | 42 |
| Metformin Hcl | Metformin Hcl | 152 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 150 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 144 | 41 |
| Lisinopril | Lisinopril | 143 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 39 |
| Jardiance | Empagliflozin | 141 | 32 |
| Simvastatin | Simvastatin | 131 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 128 | 34 |
| Meloxicam | Meloxicam | 123 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 21 |
| Bumetanide | Bumetanide | 110 | 20 |
| Trazodone Hcl | Trazodone Hcl | 110 | 25 |
| Mupirocin | Mupirocin | 109 | 66 |
| Omeprazole | Omeprazole | 109 | 31 |
| Cefuroxime | Cefuroxime Axetil | 107 | 62 |
| Mirtazapine | Mirtazapine | 104 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 20 |
| Finasteride | Finasteride | 96 | 21 |
| Aripiprazole | Aripiprazole | 94 | suppressed |
| Allopurinol | Allopurinol | 93 | 24 |
| Sucralfate | Sucralfate | 91 | 14 |
| Buspirone Hcl | Buspirone Hcl | 88 | 18 |
| Montelukast Sodium | Montelukast Sodium | 88 | 22 |
| Tramadol Hcl | Tramadol Hcl | 88 | 34 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 88 | 32 |
| Silver Sulfadiazine | Silver Sulfadiazine | 83 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 81 | 19 |
| Ozempic | Semaglutide | 79 | 21 |
| Atenolol | Atenolol | 78 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 76 | 37 |
| Xarelto | Rivaroxaban | 71 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | suppressed |
| Spironolactone | Spironolactone | 66 | 18 |
| Carvedilol | Carvedilol | 65 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 31 |
| Alprazolam | Alprazolam | 64 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 15 |
| Warfarin Sodium | Warfarin Sodium | 64 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 15 |
| Baclofen | Baclofen | 62 | suppressed |
| Digoxin | Digoxin | 61 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 60 | 17 |
| Methylprednisolone | Methylprednisolone | 59 | 48 |
| Labetalol Hcl | Labetalol Hcl | 58 | 19 |
| Famotidine | Famotidine | 56 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 55 | 13 |
| Synthroid | Levothyroxine Sodium | 55 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 53 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 51 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Pregabalin | Pregabalin | 49 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 46 | 18 |
| Linzess | Linaclotide | 46 | suppressed |
| Azithromycin | Azithromycin | 45 | 40 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Lamotrigine | Lamotrigine | 43 | suppressed |
| Prednisone | Prednisone | 43 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 42 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Risperidone | Risperidone | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 22 |
| Temazepam | Temazepam | 38 | 11 |
| Entresto | Sacubitril/Valsartan | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 22 |
| Movantik | Naloxegol Oxalate | 35 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 13 |
| Ezetimibe | Ezetimibe | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 30 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 30 | 22 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 28 | 27 |
| Carbamazepine | Carbamazepine | 28 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 22 |
| Budesonide | Budesonide | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Erythromycin | Erythromycin Base | 21 | suppressed |
| Austedo | Deutetrabenazine | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nystatin | Nystatin | 20 | 13 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 18 | 13 |
| Nadolol | Nadolol | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Modafinil | Modafinil | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Perphenazine | Perphenazine | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Ssd | Silver Sulfadiazine | 14 | 12 |
| Valsartan | Valsartan | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 13 | 13 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 12 |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vyzulta | Latanoprostene Bunod | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Meropenem | Meropenem | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $379.51 · 21 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, IBSRELA, JARDIANCE, NUZYRA, QULIPTA, REXULTI, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, WATCHMAN Access System, XIFAXAN, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error